FDA Brief

Warning letters Drugs

FDA warning letter to

Sombra Cosmetics, Inc.

High riskIssued Dec 18, 2024Posted Dec 24, 2024Center for Drug Evaluation and Research (CDER)

FDA warned Sombra Cosmetics of OTC drug CGMP violations, including inadequate water controls and component testing.

What happened

FDA inspected Sombra's Albuquerque drug manufacturing facility from July 15 to 26, 2024 and found significant CGMP (manufacturing quality rules) violations. FDA said the company did not adequately validate its water system or manufacturing processes, did not test components including APIs (active ingredients) for identity, and relied on supplier certificates without proving reliability. FDA also found microbiological water samples too numerous to count with gram-negative rods and inadequate quality unit oversight; it called the August 16, 2024 response inadequate.

What FDA found

  1. The company used water in drug manufacturing and cleaning without adequate TOC, conductivity, and microbial testing to show it was suitable, and some water samples were too numerous to count with gram-negative rods.

    21 CFR 211.100(a)
  2. The company lacked sufficient data to show its manufacturing processes were validated and its equipment qualified before commercial distribution.

    21 CFR 211.100(a)
  3. The company failed to perform adequate identity testing on each component lot, including active ingredients, and relied on supplier certificates of analysis without establishing their reliability.

    21 CFR 211.84(d)(1) and (2)
  4. The company could not show its microbiological test methods were suitable, and its growth-promotion test did not test for yeast and mold.

    21 CFR 211.160(b)
  5. The quality unit did not adequately oversee complaint investigations or establish a written stability program to set storage conditions and expiration dates.

    21 CFR 211.22(a), 211.192, 211.166(a)

What FDA wants

FDA tells Sombra to correct the violations promptly and respond in writing within 15 working days with corrective actions and supporting documents; if more time is needed, state why and give a completion schedule. FDA also asks for DEG/EG (industrial contaminants) test results within 30 calendar days and recommends a qualified CGMP consultant.

Who should pay attention

  • companies that buy or distribute Sombra OTC creams or hand sanitizers
  • OTC drug makers using water systems or supplier certificates of analysis
  • suppliers and buyers of glycerin or ethanol used in drugs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk